WebMar 28, 2024 · An Eastern Cooperative Oncology Group performance status of ≤ 2 and adequate liver, kidney, and marrow function defined as an absolute neutrophil count ≥ 1,500/μL, platelets ≥ 100,000/μL, hemoglobin ≥ 9 g/dL, total bilirubin ≤ 1.5 × the upper limit of normal (ULN), aspartate aminotransferase and alanine aminotransferase ≤ 2.5 x ULN, … WebJan 13, 2024 · Gynecol Oncol 2016; 140:409. Huang GS, Chiu LG, Gebb JS, et al. Serum CA125 predicts extrauterine disease and survival in uterine carcinosarcoma. ... Wright JD. Uterine carcinosarcoma. Curr Opin Oncol 2011; 23:531. Brooks SE, Zhan M, Cote T, Baquet CR. Surveillance, epidemiology, and end results analysis of 2677 cases of …
Dermatologic complications of anti-PD-1/PD-L1 immune …
WebJan 12, 2024 · Curr. Opin. Oncol. 28, 288–294 (2016). Article CAS Google Scholar Abdel-Rahman, O. et al. Immune-related ocular toxicities in solid tumor patients treated with immune checkpoint inhibitors ... WebMay 27, 2024 · The impact score (IS) 2024 of Current Opinion in Oncology is 3.62, which is computed in 2024 as per its definition.Current Opinion in Oncology IS is increased … birch narrows to prince albert
Current Treatment Options in Oncology Home - Springer
Web2 days ago · Aims & scope. Current Treatment Options in Oncology offers in-depth review articles contributed by international experts on the most significant developments in the field. By providing clear, insightful, balanced review articles that emphasize recently published papers of major importance, the journal elucidates current and emerging … WebLessons from recent trials. Curr Opin Oncol. 2016 Jul.28(4):359-366. Pubmedid: 27138571. Mark J, Bush S, Glazer E, Strosberg J, Saglam O, Apte SM. Metastatic VIPoma presenting as an ovarian mass. ... Fernandez H, Strosberg J, Shibata D. Synchronous rectal adenocarcinoma and splenic marginal zone lymphoma. Curr Oncol. 2016 Feb.23(1):e70 … WebBackground: Next-generation sequencing (NGS) of tumor genomes has changed and improved cancer treatment over the past few decades. It can inform clinicians on the optimal therapeutic approach in many of the solid and hematologic cancers, including non-small lung cancer (NSCLC). Our study aimed to determine the costs of NGS assays for NSCLC … birch natural assets